{"title":"Rapid response to dupilumab in an adult patient with eosinophilic esophagitis and allergic asthma.","authors":"Benjamin Klein, Regina Treudler","doi":"10.5414/ALX02485E","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus that belongs to the spectrum of Th2-mediated diseases. It is often associated with atopic comorbidities such as allergic asthma (AA) and poses a therapeutic challenge.</p><p><strong>Case report: </strong>We report on a 43-year-old patient with EoE and AA who did not show sufficient therapeutic control despite standard therapy. We started treatment with dupilumab, whereupon both EoE and AA rapidly improved and complete symptom resolution could be documented. The response to dupilumab was assessed by laboratory monitoring and gastroscopy, which showed a reduction of markers of type II inflammation and eosinophilic infiltrates in the esophagus.</p><p><strong>Summary: </strong>Our report emphasizes the effective and safe use of dupilumab as a treatment option for EoE with concomitant beneficial effects on AA.</p>","PeriodicalId":101298,"journal":{"name":"Allergologie select","volume":"8 ","pages":"78-81"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11004767/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergologie select","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5414/ALX02485E","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Eosinophilic esophagitis (EoE) is an inflammatory disease of the esophagus that belongs to the spectrum of Th2-mediated diseases. It is often associated with atopic comorbidities such as allergic asthma (AA) and poses a therapeutic challenge.
Case report: We report on a 43-year-old patient with EoE and AA who did not show sufficient therapeutic control despite standard therapy. We started treatment with dupilumab, whereupon both EoE and AA rapidly improved and complete symptom resolution could be documented. The response to dupilumab was assessed by laboratory monitoring and gastroscopy, which showed a reduction of markers of type II inflammation and eosinophilic infiltrates in the esophagus.
Summary: Our report emphasizes the effective and safe use of dupilumab as a treatment option for EoE with concomitant beneficial effects on AA.
背景：嗜酸性粒细胞食管炎（EoE）是一种食管炎症性疾病，属于Th2介导的疾病谱。它通常与过敏性哮喘（AA）等特异性合并症相关，给治疗带来了挑战：我们报告了一名 43 岁的咽喉炎和 AA 患者，尽管接受了标准治疗，但病情仍未得到充分控制。我们开始使用杜比鲁单抗治疗，患者的咽喉炎和过敏性哮喘很快得到了改善，症状完全消失。我们通过实验室监测和胃镜检查评估了患者对杜比鲁单抗的反应，结果显示 II 型炎症标志物和食管中的嗜酸性粒细胞浸润均有所减少。摘要：我们的报告强调了杜比鲁单抗作为治疗呃逆的一种有效而安全的选择，同时对 AA 也有好处。
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
